Endothelial protein C receptor–dependent antichemotactic effects of canine protein C

Valerie M. Wong Department of Pathobiology, Ontario Veterinary College, University of Guelph, Guelph, ON NIG 2WI, Canada.

Search for other papers by Valerie M. Wong in
Current site
Google Scholar
PubMed
Close
 DVM, PhD
,
Olivier Côté Department of Pathobiology, Ontario Veterinary College, University of Guelph, Guelph, ON NIG 2WI, Canada.

Search for other papers by Olivier Côté in
Current site
Google Scholar
PubMed
Close
 PhD
,
Dorothee Bienzle Department of Pathobiology, Ontario Veterinary College, University of Guelph, Guelph, ON NIG 2WI, Canada.

Search for other papers by Dorothee Bienzle in
Current site
Google Scholar
PubMed
Close
 DVM, PhD
,
M. Anthony Hayes Department of Pathobiology, Ontario Veterinary College, University of Guelph, Guelph, ON NIG 2WI, Canada.

Search for other papers by M. Anthony Hayes in
Current site
Google Scholar
PubMed
Close
 BVSc, PhD
, and
R. Darren Wood Department of Pathobiology, Ontario Veterinary College, University of Guelph, Guelph, ON NIG 2WI, Canada.

Search for other papers by R. Darren Wood in
Current site
Google Scholar
PubMed
Close
 DVM, DVSc

Abstract

OBJECTIVE To determine whether canine protein C (CnPC) had antichemotactic effects on canine neutrophils, whether endothelial protein C receptor (EPCR) was expressed on canine neutrophils, and the role of EPCR in neutrophil chemotaxis.

SAMPLE Neutrophils isolated from blood samples from healthy dogs (n = 6) and sick dogs with (2) or without (3) an inflammatory leukogram.

PROCEDURES Neutrophils were analyzed by reverse transcriptase PCR assay and flow cytometry for detection of EPCR mRNA and protein expression, respectively. Neutrophils were incubated with CnPC zymogen or canine activated protein C (CnAPC), with or without RCR-379 (an anti–human EPCR antibody). Neutrophils were then allowed to migrate through a filter membrane toward a chemokine. Untreated neutrophils served as positive control samples. Migration was quantified by fluorescence measurement, and chemotaxis index (Chx) values (fluorescence of test sample/fluorescence of positive control sample) were computed.

RESULTS The cDNA for EPCR was amplified, and EPCR expression was detected on neutrophil surfaces. Obtained Chx values were significantly higher in cells treated with RCR-379 than in cells treated with CnPC or CnAPC alone. The Chx values for neutrophils treated with RCR-379 were not significantly different from 1, whereas those for neutrophils treated without RCR-379 were significantly less than 1. The effects of RCR-379 on neutrophil migration were independent of concentration or activation status of protein C.

CONCLUSIONS AND CLINICAL RELEVANCE Canine neutrophils expressed EPCR, and inhibition of neutrophil chemotaxis by CnPC and CnAPC depended on EPCR. Interventions with EPCR signaling may have therapeutic application in dogs.

Abstract

OBJECTIVE To determine whether canine protein C (CnPC) had antichemotactic effects on canine neutrophils, whether endothelial protein C receptor (EPCR) was expressed on canine neutrophils, and the role of EPCR in neutrophil chemotaxis.

SAMPLE Neutrophils isolated from blood samples from healthy dogs (n = 6) and sick dogs with (2) or without (3) an inflammatory leukogram.

PROCEDURES Neutrophils were analyzed by reverse transcriptase PCR assay and flow cytometry for detection of EPCR mRNA and protein expression, respectively. Neutrophils were incubated with CnPC zymogen or canine activated protein C (CnAPC), with or without RCR-379 (an anti–human EPCR antibody). Neutrophils were then allowed to migrate through a filter membrane toward a chemokine. Untreated neutrophils served as positive control samples. Migration was quantified by fluorescence measurement, and chemotaxis index (Chx) values (fluorescence of test sample/fluorescence of positive control sample) were computed.

RESULTS The cDNA for EPCR was amplified, and EPCR expression was detected on neutrophil surfaces. Obtained Chx values were significantly higher in cells treated with RCR-379 than in cells treated with CnPC or CnAPC alone. The Chx values for neutrophils treated with RCR-379 were not significantly different from 1, whereas those for neutrophils treated without RCR-379 were significantly less than 1. The effects of RCR-379 on neutrophil migration were independent of concentration or activation status of protein C.

CONCLUSIONS AND CLINICAL RELEVANCE Canine neutrophils expressed EPCR, and inhibition of neutrophil chemotaxis by CnPC and CnAPC depended on EPCR. Interventions with EPCR signaling may have therapeutic application in dogs.

Contributor Notes

Address correspondence to Dr. Wong (vwong@midwestern.edu).

Dr. Wong's present address is College of Veterinary Medicine, Midwestern University, Glendale, AZ 85308.

  • 1. Fulcher CA, Gardiner JE, Griffin JH, et al. Proteolytic inactivation of human factor VIII procoagulant protein by activated human protein C and its analogy with factor V. Blood 1984; 63: 486489.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 2. Van de Waart P, Bruls H, Hemker HC, et al. Functional properties of factor Va subunits after proteolytic alterations by activated protein C. Biochim Biophys Acta 1984; 799: 3844.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 3. Esmon CT. Protein C anticoagulant system—anti-inflammatory effects. Semin Immunopathol 2012; 34: 127132.

  • 4. Shibata M, Kumar SR, Amar A, et al. Anti-inflammatory, antithrombotic, and neuroprotective effects of activated protein C in a murine model of focal ischemic stroke. Circulation 2001; 103: 17991805.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 5. Slofstra SH, Groot AP, Maris NA, et al. Inhalation of activated protein C inhibits endotoxin-induced pulmonary inflammation in mice independent of neutrophil recruitment. Br J Pharmacol 2006; 149: 740746.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 6. Mosnier LO, Griffin JH. Inhibition of staurosporine-induced apoptosis of endothelial cells by activated protein C requires protease-activated receptor-1 and endothelial cell protein C receptor. Biochem J 2003; 373: 6570.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 7. Wildhagen KC, Lutgens E, Loubele ST, et al. The structure-function relationship of activated protein C. Lessons from natural and engineered mutations. Thromb Haemost 2011; 106: 10341045.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 8. Bernard GR, Vincent JL, Laterre PF, et al. Recombinant human protein C Worldwide Evaluation in Severe Sepsis (PROWESS) study group, 2001. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001; 344: 699709.

    • Search Google Scholar
    • Export Citation
  • 9. Martí-Carvajal AJ, Solà I, Gluud C, et al. Human recombinant protein C for severe sepsis and septic shock in adult and paediatric patients. Cochrane Database Syst Rev 2012; 12: CD004388.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 10. Ranieri VM, Thompson BT, Barie PS, et al PROWESS-SHOCK Study Group. Drotrecogin alfa (activated) in adults with septic shock. N Engl J Med 2012; 366: 20552064.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 11. Eli Lilly and Company website. Lilly announces withdrawal of Xigris following recent clinical trial results. Available at: newsroom.lilly.com/releasedetail.cfm?releaseid:617602. Accessed Oct 25, 2011.

    • Search Google Scholar
    • Export Citation
  • 12. Mosnier LO, Gale AJ, Yegneswaran S, et al. Activated protein C variants with normal cytoprotective but reduced anticoagulant activity. Blood 2004; 104: 17401744.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 13. Mosnier LO, Yang XV, Griffin JH. Activated protein C mutant with minimal anticoagulant activity, normal cytoprotective activity, and preservation of thrombin activatable fibrinolysis inhibitor-dependent cytoprotective functions. J Biol Chem 2007; 282: 3302233033.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 14. Kerschen EJ, Fernandez JA, Cooley BC, et al. Endotoxemia and sepsis mortality reduction by non-anticoagulant activated protein C. J Exp Med 2007; 204: 24392448.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 15. Guo H, Singh I, Wang Y, et al. Neuroprotective activities of activated protein C mutant with reduced anticoagulant activity. Eur J Neurosci 2009; 29: 11191130.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 16. Ní Ainle F, O'Donnell JS, Johnson JA, et al. Activated protein C N-linked glycans modulate cytoprotective signaling function on endothelial cells. J Biol Chem 2011; 286: 13231330.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 17. Williams PD, Zlokovic BV, Griffin JH, et al. Preclinical safety and pharmacokinetic profile of 3K3A-APC, a novel, modified activated protein C for ischemic stroke. Curr Pharm Des 2012; 18: 42154222.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 18. de Laforcade AM, Freeman LM, Shaw SP, et al. Hemostatic changes in dogs with naturally occurring sepsis. J Vet Intern Med 2003; 17: 674679.

  • 19. de Laforcade AM, Rozanski EA, Freeman LM, et al. Serial evaluation of protein C and antithrombin in dogs with sepsis. J Vet Intern Med 2008; 22: 2630.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 20. Fourrier F, Chopin C, Guodemand J, et al. Septic shock, multiple organ failure, and disseminated intravascular coagulation. Compared patterns of antithrombin III, protein C, and protein S deficiencies. Chest 1992; 101: 816823.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 21. Lorente JA, García-Frade LJ, Landín L, et al. Time course of hemostatic abnormalities in sepsis and its relation to outcome. Chest 1993; 103: 15361542.

  • 22. Leeb T, Kopp T, Deppe A, et al. Molecular characterization and chromosomal assignment of the canine protein C gene. Mamm Genome 1999; 10: 134139.

  • 23. Wang Y, Zhang Z, Chow N, et al. An activated protein C analog with reduced anticoagulant activity extends the therapeutic window of tissue plasminogen activator for ischemic stroke in rodents. Stroke 2012; 43: 24442449.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 24. Boppana NB, Devarajan A, Gopal K, et al. Blockade of CXCR2 signalling: a potential therapeutic target for preventing neutrophil-mediated inflammatory diseases. Exp Biol Med (Maywood) 2014; 239: 509518.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 25. Wong VM, Bienzle D, Hayes MA, et al. Purification of protein C from canine plasma. BMC Vet Res 2014; 10: 251.

  • 26. Sturn DH, Kaneider NC, Feistritzer, et al. Expression and function of the endothelial protein C receptor in human neutrophils. Blood 2003; 102: 14991505.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 27. Nick JA, Coldren CD, Geraci MW, et al. Recombinant human activated protein C reduces human endotoxin-induced pulmonary inflammation via inhibition of neutrophil chemotaxis. Blood 2004; 104: 38783885.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 28. Galley HF, El Sakka NE, Webster NR, et al. Activated protein C inhibits chemotaxis and interleukin-6 release by human neutrophils without affecting other neutrophil functions. Br J Anaesth 2008; 100: 815819.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 29. Xue M, March L, Sambrook PN, et al. Endothelial protein C receptor is overexpressed in rheumatoid arthritic (RA) synovium and mediates the anti-inflammatory effects of activated protein C in RA monocytes. Ann Rheum Dis 2007; 66: 15741580.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation

Advertisement